Visual Field Changes in Pediatric and Adolescent Patients Treated with Vigabatrin.
- Author:
Cinoo KIM
1
;
Jeong Hun KIM
;
Ho Kyung CHOUNG
;
Seong Joon KIM
;
Young Suk YU
Author Information
1. Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea. ysyu@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Mean radial degrees;
Vigabatrin;
Visual field constriction
- MeSH:
Adolescent*;
Anticonvulsants;
Constriction;
Humans;
Seizures;
Vigabatrin*;
Visual Field Tests;
Visual Fields*
- From:Journal of the Korean Ophthalmological Society
2007;48(4):547-554
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To investigate perimetric changes in pediatric and adolescent patients treated with vigabatrin and to assess the relationship between the visual field defect and the cumulative dose, the duration of treatment, or the age when vigabatrin was first taken. METHODS: Pediatric and adolescent patients treated with vigabatrin for seizure for at least 6 months were examined with Goldmann perimetry. The cumulative dose, the duration of treatment, the age when vigabatrin was first taken, and whether a combination of anticonvulsants and vigabatrin was taken were recorded. Mean radial degree (MRD) determination from the right eye was used to compare the amount of constriction. RESULTS: Visual field constriction developed in 19 (27.1%) out of 70 patients and MRD decreased by 22.7% a mean duration of 86.7+/-27.4 months of treatment. The visual field significantly decreased in the superior, nasal, and inferior field with temporal and central sparing (p<0.001). There was a statistically significant correlation between the average MRD and the cumulative dose (r2=0.1772, p<0.001), and the duration of treatment (r2=0.1713, p<0.001), but no correlation between the average MRD and either the age when vigabatrin was first taken, or the combination of anticonvulsants with vigabatrin. CONCLUSIONS: Visual field constriction developed in one quarter of pediatric and adolescent patients treated with vigabatrin, which significantly correlated with the cumulative dose and the duration of treatment. Therefore, a regular examination of the visual field is warranted for pediatric and adolescent patients treated with vigabatrin.
